MCMaria Teresa Catanese

Maria Teresa Catanese

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Teresa Catanese has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Charles M. Rice

    The Rockefeller University

    3 shared publications
  • Alexander Ploss

    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Diseases, The Rockefeller University, New York, NY

    2 shared publications
  • Charles M. Rice

    Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA

    2 shared publications
  • Christopher T. Jones

    Center for the study of Hepatitis C, The Rockefeller University, New York, NY, USA

    2 shared publications
  • John W. Schoggins

    Center for the study of Hepatitis C, The Rockefeller University, New York, NY, USA

    2 shared publications
  • Walter T. Barry

    Center for the study of Hepatitis C, The Rockefeller University, New York, NY, USA

    2 shared publications

Latest Publications

  • Open Access

    Advancement in Cellular Topographic and Nanoparticle Capture Imaging by High Resolution Microscopy Incorporating a Freeze-Drying and Gaseous Nitrogen-based Approach

    by Kunihiro Uryu, Nadine Soplop, Timothy P. Sheahan, Maria-Teresa Catanese, Chuong Huynh, John Pena, Nancy Boudreau, Irina Matei, Candia Kenific, Ayako Hashimoto, et al.

    Scanning electron microscopy (SEM) offers an unparalleled view of the membrane topography of mammalian cells by using a conventional osmium (OsO 4 ) and ethanol-based tissue preparation. However, conventional SEM methods limit optimal resolution due to ethanol and lipid interactions and interfere with visualization of fluorescent reporter proteins. Therefore, SEM correlative light and electron microscopy (CLEM) has been hindered by the adverse effects of ethanol and OsO 4 on retention of fluorescence signals. To overcome this technological gap in achieving high-resolution SEM and retain fluorescent reporter signals, we developed a freeze-drying method with gaseous nitrogen (FDGN). We demonstrate that FDGN preserves cyto-architecture to allow visualization of detailed membrane topography while retaining fluorescent signals and that FDGN processing can be used in conjunction with a variety of high-resolution imaging systems to enable collection and validation of unique, high-quality data from these approaches. In particular, we show that FDGN coupled with high resolution microscopy provided detailed insight into viral or tumor-derived extracellular vesicle (TEV)-host cell interactions and may aid in designing new approaches to intervene during viral infection or to harness TEVs as therapeutic agents.

  • Open Access

    A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo

    by Philip Meuleman, Maria Teresa Catanese, Lieven Verhoye, Isabelle Desombere, Ali Farhoudi, Christopher T. Jones, Timothy Sheahan, Katarzyna Grzyb, Riccardo Cortese, Charles M. Rice, et al.

    Endstage liver disease caused by chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the Western world. However, immediate reinfection of the grafted donor liver by circulating virus is inevitable and liver disease progresses much faster than the original disease. Standard antiviral therapy is not well tolerated and usually ineffective in liver transplant patients, whereas anti-HCV immunotherapy is hampered by the extreme genetic diversity of the virus and its ability to spread by way of cell-cell contacts. We generated a human monoclonal antibody against scavenger receptor class B type I (SR-BI), monoclonal antibody (mAb)16-71, which can efficiently prevent infection of Huh-7.5 hepatoma cells and primary hepatocytes by cell-culture-derived HCV (HCVcc). Using an Huh7.5 coculture system we demonstrated that mAb16-71 interferes with direct cell-to-cell transmission of HCV. Finally we evaluated the in vivo efficacy of mAb16-71 in “human liver urokinase-type plasminogen activator, severe combined immune deficiency (uPA-SCID) mice” (chimeric mice). A 2-week anti-SR-BI therapy that was initiated 1 day before viral inoculation completely protected all chimeric mice from infection with serum-derived HCV of different genotypes. Moreover, a 9-day postexposure therapy that was initiated 3 days after viral inoculation (when viremia was already observed in the animals) suppressed the rapid viral spread observed in untreated control animals. After cessation of anti-SR-BI-specific antibody therapy, a rise of the viral load was observed. Conclusion : Using in vitro cell culture and human liver-chimeric mouse models, we show that a human mAb targeting the HCV coreceptor SR-BI completely prevents infection and intrahepatic spread of multiple HCV genotypes. This strategy may be an efficacious way to prevent infection of allografts following liver transplantation in chronic HCV patients, and may even hold promise for the prevention of virus rebound during or following antiviral therapy. (Hepatology 2012)


  • Open Access

    A genetically humanized mouse model for hepatitis C virus infection

    by Marcus Dorner, Joshua A. Horwitz, Justin B. Robbins, Walter T. Barry, Qian Feng, Kathy Mu, Christopher T. Jones, John W. Schoggins, Maria Teresa Catanese, Dennis R. Burton, et al.

    The development of therapies for hepatitis C virus (HCV) infection has been hampered by the lack of a small-animal model of the disease. Now Alexander Ploss and colleagues describe the first immunocompetent rodent model for hepatitis C virus infection, using adenoviruses expressing four human factors to enable entry of HCV into mouse cells. These vectors were then used to transduce the livers of mice, which then became susceptible to HCV infection. Although the model does not enable a complete virus replication cycle, it should be useful for the evaluation of HCV vaccines and entry inhibitors. Hepatitis C virus (HCV) remains a major medical problem. Antiviral treatment is only partially effective and a vaccine does not exist. Development of more effective therapies has been hampered by the lack of a suitable small animal model. Although xenotransplantation of immunodeficient mice with human hepatocytes has shown promise, these models are subject to important challenges. Building on the previous observation that CD81 and occludin comprise the minimal human factors required to render mouse cells permissive to HCV entry in vitro4, we attempted murine humanization via a genetic approach. Here we show that expression of two human genes is sufficient to allow HCV infection of fully immunocompetent inbred mice. We establish a precedent for applying mouse genetics to dissect viral entry and validate the role of scavenger receptor type B class I for HCV uptake. We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge. This system recapitulates a portion of the HCV life cycle in an immunocompetent rodent for the first time, opening opportunities for studying viral pathogenesis and immunity and comprising an effective platform for testing HCV entry inhibitors in vivo.


  • Open Access

    Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells

    by Linda Andrus, Svetlana Marukian, Christopher T. Jones, Maria Teresa Catanese, Timothy P. Sheahan, John W. Schoggins, Walter T. Barry, Lynn B. Dustin, Kartik Trehan, Alexander Ploss, et al.

    Here we demonstrate that primary cultures of human fetal liver cells (HFLC) reliably support infection with laboratory strains of hepatitis C virus (HCV), although levels of virus replication vary significantly between different donor cell preparations and frequently decline in a manner suggestive of active viral clearance. To investigate possible contributions of the interferon (IFN) system to control HCV infection in HFLC, we exploited the well-characterized ability of paramyxovirus (PMV) V proteins to counteract both IFN induction and antiviral signaling. The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC using lentiviral vectors encoding a fluorescent reporter for visualization of HCV-infected cells. V protein-transduced HFLC supported enhanced (10 to 100-fold) levels of HCV infection relative to untransduced or control vector-transduced HFLC. Infection was assessed by measurement of virus-driven luciferase, by assays for infectious HCV and viral RNA, and by direct visualization of HCV-infected hepatocytes. Live cell imaging between 48 and 119 hours postinfection demonstrated little or no spread of infection in the absence of PMV V protein expression. In contrast, V protein-transduced HFLC showed numerous HCV infection events. V protein expression efficiently antagonized the HCV-inhibitory effects of added IFNs in HFLC. In addition, induction of the type III IFN, IL29, following acute HCV infection was inhibited in V protein-transduced cultures. Conclusion: These studies suggest that the cellular IFN response plays a significant role in limiting the spread of HCV infection in primary hepatocyte cultures. Strategies aimed at dampening this response may be key to further development of robust HCV culture systems, enabling studies of virus pathogenicity and the mechanisms by which HCV spreads in its natural host cell population. (Hepatology 2011;)


  • Open Access

    Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system

    by Christopher T Jones, Maria Teresa Catanese, Lok Man J Law, Salman R Khetani, Andrew J Syder, Alexander Ploss, Thomas S Oh, John W Schoggins, Margaret R MacDonald, Sangeeta N Bhatia, et al.

    Hepatitis C virus research is hampered by the inability to detect individual infected cells. Jones et al. achieve this by imaging the translocation of a fluorescent reporter protein after cleavage by a viral protease in living or fixed cells. Hepatitis C virus (HCV), which infects 2–3% of the world population, is a causative agent of chronic hepatitis and the leading indication for liver transplantation1. The ability to propagate HCV in cell culture (HCVcc) is a relatively recent breakthrough and a key tool in the quest for specific antiviral therapeutics. Monitoring HCV infection in culture generally involves bulk population assays, use of genetically modified viruses and/or terminal processing of potentially precious samples. Here we develop a cell-based fluorescent reporter system that allows sensitive distinction of individual HCV-infected cells in live or fixed samples. We demonstrate use of this technology for several previously intractable applications, including live-cell imaging of viral propagation and host response, as well as visualizing infection of primary hepatocyte cultures. Integration of this reporter with modern image-based analysis methods could open new doors for HCV research.


  • AROS-29 is involved in adaptive response to oxidative stress

    by Nicola Montesano Gesualdi, Giuseppa Chirico, Maria Teresa Catanese, Giuseppe Pirozzi, Franca Esposito

    Transient adaptation to mild oxidative stress was induced in human osteosarcoma cells chronically grown in sub-toxic concentrations of diethylmaleate (DEM), a glutathione (GSH) depleting agent. The adapted cells, compared to untreated cells, contain increased concentrations of GSH (4-6 fold) which, upon DEM withdrawal from the culture medium, return to normal values and are more resistant to subsequent oxidizing stress induced either by toxic concentrations of the same agent or by (H(2)O(2)) treatment. To investigate the molecular mechanisms involved in the adaptive response to oxidative stress, we analyzed the gene expression profiles of DEM-adapted cells by differential display. The expression of adaptive response to oxidative stress (AROS)-29 gene, coding for a transmembrane protein of unknown function, as well as of some known genes involved in energy metabolism, protein folding and membrane traffic is up-regulated in adapted cells. The increased resistance to both DNA damage and apoptosis, in cells stably overexpressing AROS-29, demonstrated its functional role in the protection against oxidative stress.